Iradimed (Nasadq:IRMD) announced that it voluntarily withdrew an FDA 510(k) application for its new model MR IV pump. Winter Springs, Florida-based Iradimed said it learned that the FDA likely wouldn’t have time to finish clearance activities for the pending submission. Upon learning this, the company decided to voluntarily withdraw its application on Oct. 5. The […]
MassDevice Earnings Roundup
Analysts see multi-year transition to growth for Embecta
Embecta (Nasdaq:EMBC), the BD diabetes business spinoff, may take a few years to move into a growth phase, analysts say. BTIG analysts Marie Thibault and Sam Eiber wrote a report labeling Embecta as a “Neutral” option on the market. BD initially announced it would spin off its diabetes business in 2021, finally completing the move […]
Embecta stock soars on first full-quarter results after BD spinoff
Embecta (Nasdaq: EMBC) today posted third-quarter results today for the first time as a BD (NYSE: BDX) spinoff, beating the consensus forecast on Wall Street. The Parsippany, New Jersey-based diabetes technology company reported profits of $62.4 million, or $1.08 per share, on sales of $291.1 million for the three months ended June 30. RELATED: How […]
Senseonics stock is up as it sticks by revenue guidance
Senseonics (NYSE:SENS) shares were up slightly today on second-quarter results that came up shy of the consensus forecast. The Germantown, Maryland-based continuous glucose monitoring technology developer yesterday evening posted profits of $103.9 million, or 22¢ per share, on sales of $3.7 million for the three months ended June 30, 2022, for a massive bottom-line gain […]
Insulet up on Q2 sales beat, raised full-year guidance
Insulet (Nasdaq:PODD) stock is up today — a day after releasing Q2 results that blew past the consensus revenue forecast. The Acton, Massachusetts–based automated insulin delivery technology developer yesterday evening posted losses of $35 million, or 50¢ per share, on sales of $299.4 million for the three months ended June 30, 2022, for a $10 […]
Tandem sinks on Q2 misses, slashed sales guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares took a bit hit after hours on second-quarter results that missed the consensus forecast. Shares of TNDM were down 7.2% at $64 per share after the market closed, which was when it released its quarterly results. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device […]
Dexcom stock dips on missed Q2 projections with broader G7 launch ‘in coming weeks’
Dexcom (Nasdaq:DXCM) shares took a hit after hours today on second-quarter results that came up shy of the consensus forecast. Shares of DXCM were down 7.2% at $80.69 after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 2.4%. The San […]
West Pharmaceutical stock ticks up on Street-beating Q2 despite lowered guidance
West Pharmaceutical Services (NYSE:WST) shares rose before hours on second-quarter results that came in ahead of the consensus forecast. The Exton, Pennsylvania–based company posted profits of $188.5 million, or $2.48 per share, on sales of $771.3 million for the three months ended June 30, 2022, for a 0.6% bottom-line gain on sales growth of 6.6%. […]
Medtronic ‘hopeful’ on FDA clearance for next-gen diabetes tech in FY 2023
The Medtronic (NYSE:MDT) diabetes business sputtered in the fourth quarter but could be bolstered by a major regulatory nod this year. The Fridley, Minnesota-based company saw revenues for its diabetes arm fall by 7.7% year-over-year in the fourth quarter amid overall misses on both sales and adjusted earnings per share compared to Wall Street’s expectations. […]
Senseonics beats The Street in Q1 following Eversense E3 launch
Senseonics (NYSE:SENS) posted first-quarter results that topped the consensus revenue forecast on Wall Street. The Germantown, Maryland-based company posted profits of $86.7 million, or 19¢ per share, on sales of $2.5 million for the three months ended March 31, 2022, for a massive bottom-line gain from losses of $249.5 million this time last year despite […]